P. Nielsen et al.
bate (135 mg, 0.67 mmol) and CuSO4·5H2O (90 mg, 0.18 mmol) were
added to a stirred solution of compound 11 (590 mg, 0.88 mmol) and 1N-
benzoyl-5-ethynyluracil (280 mg, 1.17 mmol) in a mixture of tBuOH,
water and pyridine (12 mL, 5:5:2, v/v). The reaction mixture was stirred
at room temperature for 24 h. CH2Cl2 (50 mL) was added and the mix-
ture was washed with a 10% aqueous solution of NaHCO3. The aqueous
phase was extracted with CH2Cl2 (3ꢃ30 mL), and the combined organic
phase was dried (Na2SO4) and concentrated under reduced pressure. The
residue was purified by column chromatography (1–3% MeOH in
CH2Cl2) to give product 15 as a white foam (650 mg, 81%). Rf =0.32
(CH2Cl2/MeOH, 95:5, v/v); 1H NMR (300 MHz, CDCl3): d=10.37 (brs,
1H; NH), 8.88 (s, 1H; NH), 8.28 (s, 1H; triazole), 7.98–7.95 (m, 2H; Bz),
7.83 (s, 1H; H-6), 7.67–7.64 (m, 2H; H-6, Bz), 7.53–6.96 (m, 15H; pixyl,
Bz), 6.12 (dd, J=4.8, 9.4 Hz, 1H; H-1’), 4.12 (dd, J=8.7, 13.6 Hz, 1H; H-
6’), 3.73–3.70 (m, 1H; H-5’), 3.60 (dd, J=3.6, 13.6 Hz, 1H; H-6’), 3.35 (s,
1H; H-4’), 3.18 (d, J=4.8 Hz, 1H; H-3’), 2.04 (s, 3H; CH3(T)), 1.95 (m,
acetylene (TMSA; 43 mL, 0.30 mmol) in a mixture of tBuOH, water and
pyridine (2.5 mL, 5:5:2, v/v). The reaction mixture was stirred at room
temperature for 16 h. Additional portions of TMSA (43 mL, 0.30 mmol),
sodium ascorbate (15 mg, 0.15 mmol) and CuSO4·5H2O (10 mg,
0.021 mmol) were added, and the reaction mixture was stirred for a fur-
ther 3 h. CH2Cl2 (30 mL) was added and the mixture was washed with a
10% aqueous solution of NaHCO3. The aqueous phase was extracted
with CH2Cl2 (3ꢃ30 mL), and the combined organic phase was dried
(Na2SO4) and concentrated under reduced pressure. The residue was pu-
rified by column chromatography (1–3% MeOH in CH2Cl2) to give prod-
uct 18 as
a white foam (203 mg, 88%). Rf =0.38 (CH2Cl2/MeOH,
1
97.5:2.5, v/v); H NMR (300 MHz, CDCl3): d=8.55 (s, 1H; NH), 7.78 (d,
J=1.2 Hz, 1H; H-6), 7.48–7.26 (m, 10H; triazole, pixyl), 7.13–6.98 (m,
4H; pixyl), 6.12 (dd, J=5.1, 9.6 Hz, 1H; H-1’), 4.08 (dd, J=9.9, 14.1 Hz,
1H; H-6’), 3.78–3.73 (m, 2H; H-6’, H-5’), 3.18–3.15 (m, 2H; H-4’, H-3’),
2.05 (d, J=0.6 Hz, 3H; CH3(T)), 1.90 (m, 1H; H-2’), 1.83 (m, 1H; H-2’),
1H; H-2’), 1.80 (m, 1H; H-2’), 0.67 (s, 9H; C
(CH3)3), À0.21 (s, 3H;
0.68 (s, 9H; C
N
N
CH3Si), À0.32 ppm (s, 3H; CH3Si); 13C NMR (75 MHz, CDCl3): d=168.4
(C=O), 164.1, 160.7 (C-4), 152.0 (pixyl), 150.4, 150.2 (C-2b), 146.1, 138.6,
138.6, 136.9, 135.9, 135.4, 131.4, 131.0, 130.6, 130.6, 129.4, 128.1, 127.7,
124.1, 124.0, 123.4, 122.9, 122.2 (C-6, tetrazole, Bz, pixyl), 117.5, 117.1
(pixyl), 110.8, 105.9 (C-5), 86.8 (C-4’), 85.0 (C-1’), 78.8 (pixyl), 73.3 (C-
À0.34 ppm (s, 3H; CH3Si); 13C NMR (75 MHz, CDCl3): d=163.7 (C-4),
152.2, 151.9 (pixyl), 150.4 (C-2), 146.3 (triazole), 135.8 (C-6), 131.2, 130.8,
130.5, 130.0, 128.1, 127.7, 124.0, 123.9, 122.9, 122.3, 117.6, 117.1 (pixyl, tri-
azole), 111.3 (C-5), 86.4 (C-4’), 84.5 (C-1’), 78.8 (pixyl), 72.9 (C-3’), 72.0
(C-5’), 49.2 (C-6’), 40.8 (C-2’), 25.6 (CACTHUNTRGENNUG(CH3)3), 17.7 (CCAHTUNTGREN(NUGN CH3)3), 12.8
3’), 71.8 (C-5’), 50.4 (C-6’), 40.9 (C-2’), 25.7 (C
(CH3)3), 17.7 (C
N
(CH3(T)), 1.0 (Si
G
12.8 (CH3(T)), À4.5, À4.7 ppm (CH3Si); HRMS (ESI): m/z: calcd for
calcd for C41H51N5O6Si2Na+ [M+Na]+: 788.3270; found: 788.3232.
C49H49N7O9SiNa+ [M+Na]+: 930.3253; found: 930.3238.
Synthesis of 5’-O-pixyl-5’-(S)-C-(1,2,3-triazol-1-yl)methylthymidine (19):
A 1.0m solution of TBAF in THF (2 mL, 2.00 mmol) was added to a
stirred solution of compound 18 (350 mg, 0.44 mmol) in anhydrous THF
(4 mL). The reaction mixture was stirred at room temperature for 55 h.
CH2Cl2 (25 mL) was added and the mixture was washed with a 10%
aqueous solution of NaHCO3 (15 mL). The aqueous phase was extracted
with CH2Cl2 (3ꢃ30 mL) and the combined organic phase was dried
(Na2SO4) and concentrated under reduced pressure. The residue was pu-
rified by column chromatography (2–3% MeOH in CH2Cl2) to give prod-
uct 19 as a white foam (250 mg, 94%). Rf =0.18 (CH2Cl2/MeOH, 95:5, v/
v); 1H NMR (300 MHz, CDCl3): d=9.36 (s, 1H; NH), 7.57–7.00 (m,
16H; H-6, triazole, pixyl), 6.10 (t, J=6.9 Hz, 1H; H-1’), 4.08 (dd, J=8.4,
14.4 Hz, 1H; H-6’), 3.83–3.77 (m, 2H; H-6’, H-5’), 3.53 (m, 1H; H-3’),
3.30 (t, J=3.6 Hz, 1H; H-4’), 2.82 (d, J=3.9 Hz, 1H; OH-5’), 2.12 (m,
1H; H-2’), 2.00 (s, 3H; CH3), 1.96 ppm (m, 1H; H-2’); 13C NMR
(75 MHz, CDCl3): d=163.7 (C-4), 152.0 (pixyl), 150.2 (C-2), 146.4
(pixyl), 136.0 (C-6), 133.9, 131.2, 131.2, 130.7, 130.4, 128.1, 127.6, 124.8,
124.0, 123.7, 122.6, 117.4, 116.9 (pixyl, triazole), 111.3 (C-5), 84.7 (C-4’),
84.0 (C-1’), 78.2 (pixyl), 71.1 (C-5’), 70.1 (C-3’), 49.9 (C-6’), 40.0 (C-2’),
12.8 ppm (CH3); HRMS (ESI): m/z: calcd for C32H29N5O6Na+ [M+Na]+:
602.2010; found: 602.2040.
Synthesis of 5’(S)-C-(4-(1N-benzoyluracil-5-yl)-1,2,3-triazol-1-yl)methyl-
5’-O-pixyl-thymidine (16): A 1.0m solution of TBAF in THF (1.0 mL,
1.0 mmol) was added to a stirred solution of compound 15 (575 mg,
0.52 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred
at room temperature for 24 h under Ar. CH2Cl2 (40 mL) was added and
the mixture was washed with a 10% aqueous solution of NaHCO3
(20 mL). The aqueous phase was extracted with CH2Cl2 (3ꢃ40 mL) and
the combined organic phase was dried (Na2SO4) and concentrated under
reduced pressure. The residue was purified by column chromatography
(2–5% MeOH in CH2Cl2) to give product 16 as a white foam (424 mg,
86%). Rf =0.27 (CH2Cl2/MeOH, 95:5, v/v); 1H NMR (300 MHz,
[D6]DMSO): d=11.91 (brs, 1H; NH), 11.35 (s, 1H; NH), 8.20 (s, 1H; tri-
azole), 8.03 (d, J=7.2 Hz, 2H; Bz), 7.89 (s, 1H; H-6), 7.80 (m, 1H; Bz),
7.61 (t, J=7.8 Hz, 2H; Bz), 7.50 (s, 1H; H-6), 7.42–6.92 (m, 13H; pixyl),
5.90 (t, J=7.5 Hz, 1H; H-1’), 4.98 (d, J=4.2 Hz, 1H; OH-3’), 4.27 (dd,
J=9.3, 15.0 Hz, 1H; H-6’), 3.77–3.70 (m, 2H; H-6’, H-5’), 3.41 (m, 1H;
H-3’), 3.15 (m, 1H; H-4’), 1.90–1.84 ppm (m, 5H; H-2’, CH3); 13C NMR
(75 MHz, [D6]DMSO): d=169.6 (C=O), 163.7, 160.7 (C-4), 151.0, 150.9
(C-2), 150.2, 149.1, 147.1, 138.4, 138.2, 135.5, 135.4, 131.2, 130.9, 130.4,
129.5, 128.8, 128.1, 127.8, 125.3, 123.7, 123.6, 122.6, 122.4, 122.0 (C-6, tet-
razole, Bz, pixyl), 116.7, 116.2 (pixyl), 109.5, 103.8 (C-5), 85.0 (C-4’), 83.6
(C-1’), 77.2 (pixyl), 71.8 (C-5’), 70.1 (C-3’), 49.5 (C-6’), 40.0 (C-2’),
12.3 ppm (CH3); HRMS (ESI): m/z: calcd for C43H35N7O9Na+ [M+Na]+:
816.2388; found: 816.2407.
Synthesis of 3’-O-(P-2-cyanoethoxy-N,N-diisopropylaminophosphinyl)-5’-
O-pixyl-5’-(S)-C-(1,2,3-triazol-1-yl)methylthymidine (20): N,N-Diisopro-
pylethylamine (130 mL, 0.75 mmol) and 2-cyanoethyl-N,N-diisopropyl-
phosphoramidochloridite (125 mL, 0.56 mmol) were added to a stirred so-
lution of compound 19 (100 mg, 0.17 mmol) in anhydrous CH2Cl2 (2 mL).
The reaction mixture was stirred at room temperature for 2 h. CH2Cl2
(30 mL) was added and the mixture was washed with a 10% aqueous so-
lution of NaHCO3. The aqueous phase was extracted with CH2Cl2 (3ꢃ
30 mL) and the combined organic phase was dried (Na2SO4) and concen-
trated under reduced pressure. The residue was purified by column chro-
matography (0–2% acetone in CH2Cl2) to give product 20 as a white
foam (81 mg, 60%). Rf =0.49, 0.45 (CH2Cl2/acetone, 3:1, v/v); 31P NMR
(75 MHz, CDCl3): d=151.48, 151.23 ppm; HRMS (ESI): m/z: calcd for
C41H46N7O7PNa+ [M+Na]+: 802.3089; found: 802.3086.
Synthesis of 5’-(S)-C-(4-(1N-benzoyluracil-5-yl)-1,2,3-triazol-1-yl)methyl-
3’-O-(P-2-cyanoethoxy-N,N-diisopropylaminophosphinyl)-5’-O-pixylthy-
midine (17): N,N-Diisopropylethylamine (130 mL, 0.75 mmol) and 2-cya-
noethyl-N,N-diisopropylphosphoramidochloridite (125 mL, 0.56 mmol)
were added to a stirred solution of compound 16 (100 mg, 0.13 mmol) in
anhydrous CH2Cl2 (2 mL). The reaction mixture was stirred at room tem-
perature for 2 h. Then CH2Cl2 (30 mL) was added and the mixture was
washed with a 10% aqueous solution of NaHCO3. The aqueous phase
was extracted with CH2Cl2 (3ꢃ30 mL) and the combined organic phase
was dried (Na2SO4) and concentrated under reduced pressure. The resi-
due was purified by column chromatography (0–20% acetone in CH2Cl2)
to give product 17 as a white foam (90 mg, 70%). Rf =0.51, 0.53 (CH2Cl2/
acetone, 3:1, v/v); 31P NMR (75 MHz, CDCl3): d=151.92, 151.13 ppm;
HRMS (ESI): m/z: calcd for C52H52N9O10PNa+ [M+Na]+: 1016.3467;
found: 1016.3513.
Synthesis of 3’-O-(tert-butyldimethylsilyl)-5’-(S)-C-(1-pivaloyloxymethyl-
1,2,3-triazol-4-yl)methylthymidine (22): NaN3 (335 mg, 5.15 mmol),
sodium ascorbate (55 mg, 0.28 mmol), CuI (100 mg, 0.52 mmol) and N,N’-
dimethylethylenediamine (80 mL, 0.75 mmol) were added to a stirred so-
lution of pivaloyloxymethyl chloride (750 mL, 5.15 mmol) in a mixture of
EtOH and water (8 mL, 7:3, v/v), and the reaction mixture was stirred
under MW at 1008C for 1 h. Then compound 21 (520 mg, 1.31 mmol),
NaN3 (335 mg, 5.15 mmol), sodium ascorbate (55 mg, 0.28 mmol), CuI
(100 mg, 0.52 mmol) and N,N’-dimethylethylenediamine (80 mL,
Synthesis of 3’-O-(tert-butyldimethylsilyl)-5’-O-pixyl-5’-(S)-C-(4-trime-
thylsilyl-1,2,3-triazol-1-yl)methylthymidine (18): Sodium ascorbate
(15 mg, 0.15 mmol) and CuSO4·5H2O (10 mg, 0.021 mmol) were added to
a stirred solution of compound 11 (200 mg, 0.30 mmol) and trimethylsilyl
12916
ꢀ 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Chem. Eur. J. 2010, 16, 12904 – 12919